← Back to Search

Antibiotic

AEMCOLO (Rifamycin SV MMX) for Gastrointestinal Disease

Phase 2

Waitlist Available

Research Sponsored by Bradley Connor

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 month after treatment

Awards & highlights

Study Summary

This trial is testing AEMCOLO, a new antibiotic, to see if it effectively treats Small intestinal bacterial overgrowth (SIBO).

Eligible Conditions

Gastrointestinal Disease
Small Intestinal Bacterial Overgrowth
Gastroenteritis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 month after treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 month after treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month after treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To assess the change of an abnormal breath test followed by a regimen of AEMCOLO

Secondary outcome measures

To evaluate the change in clinical symptoms followed by a regimen of AEMCOLO

Trial Design

2Treatment groups

Experimental Treatment

Group I: 2nd regimenExperimental Treatment1 Intervention

15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg tablets to take two tablets three times daily for 14 days (84 Tablets).

Group II: 1st regimenExperimental Treatment1 Intervention

15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg two tablets to take twice daily for 14 days (56 Tablets)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bradley ConnorLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the current enrollment period still accepting participants?

"According to clinicaltrials.gov, this medical experiment is no longer in the recruitment stage. The trial was made available on June 30th 2020 and underwent its last revision April 29th 2022. Despite being closed for enrollment, there are still 77 other trials seeking patients at present."

Answered by AI

What is the maximum capacity of participants in this experiment?

"This trial has ceased participant recruitment; it was first advertised on June 30th 2020 and edited for the last time April 29th 2022. However, there are currently 73 analyses looking to recruit patients with cholera infantum and 4 additional studies researching AEMCOLO (Rifamycin SV MMX)."

Answered by AI

Who meets the criteria to take part in this medical research?

"This medical trial is open to individuals aged 18-70 with a diagnosis of cholera infantum. The overall recruitment goal for this study is 30 participants."

Answered by AI

Are there any other studies that have utilized AEMCOLO (Rifamycin SV MMX)?

"Currently, 4 studies are being conducted on AEMCOLO (Rifamycin SV MMX) with none in the third phase of testing. Two locations across New york City are conducting trials for this medication, however most research is concentrated in one area."

Answered by AI

What potential risks are there when utilizing AEMCOLO (Rifamycin SV MMX) in clinical care?

"Our evaluation of AEMCOLO (Rifamycin SV MMX) suggests that it is relatively safe, earning a score of 2. This is because there are studies backing its safety but yet to be any evidence in support of efficacy."

Answered by AI